BriaCell Announces Closing of Upsized & Oversubscribed

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
2,115
BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million

BERKELEY, Calif., and VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V: BCT ) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed the second and final tranche of its previously-announced non-brokered private placement (the " Second Tranche ") of common shares in the capital of the Company.  Under the Second Tranche, the Company issued a total of 22,235,240 common shares at a price of C$0.10 per common share for gross proceeds of C$2,223,524.  Combined with the closing of the first tranche on March 25, 2019 (the " First Tranche "), the Company has issued a total of 29,735,240 common shares for gross proceeds of C$2,973,524, upsized from its “up to approximately C$2 million” private placement (collectively with the First Tranche and Second Tranche, the “ Private Placement ”). The Private Placement size is inclusive of the C$500,000 equity investment by BriaCell Director and Acting Chairman of the Board, Jamieson Bondarenko, which closed as part of the first tranche on March 25, 2019 (" Bondarenko Investment ", collectively with the Private Placement, the " Offering ").  The terms and conditions of the Private Placement and Bondarenko Investment are the same.

The Company intends to use the net proceeds from the Offering: (i) to finance the Company's Phase IIa combination study of Bria-IMT™ with KEYTRUDA® by Merck & Co. Inc. (NYSE: MRK) in advanced breast cancer; (ii) to finance the Company's pursuit of other research opportunities; and (iii) for working capital and general corporate purposes.

All securities issued under the First Tranche will be subject to a hold period expiring on July 26, 2019. All securities issued under the Second Tranche will be subject to a hold period expiring on July 30, 2019. The Company paid a total of C$139,340 cash finders’ fees on subscriptions under the Offering.

Jamieson Bondarenko is an insider of the Company, and his participation in the Private Placement is considered a "related party transaction" pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the insiders' participation in the Private Placement in reliance of sections 5.5(a) and 5.7(1)(a) of MI 61-101.

The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Separately, the Company has made an application to the TSX Venture Exchange (the " Exchange ") to amend the exercise price of approximately 12,453,000 common share purchase warrants (the " Warrants ") which were or will be issued to current BriaCell noteholders upon conversion of convertible notes issued as part of a previous  private placement, which closed last year on March 8, 2018 (see press release dated March 7, 2018). Subject to Exchange approval, the Company intends to amend the exercise price of the Warrants from C$0.14 to C$0.12. All other terms of the Warrants remain the same. The Warrants are not owned by, directly or indirectly, any of the Company's directors, officers or control persons.

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.

BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination study with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]. The combination study is listed in ClinicalTrials.gov as NCT03328026.

BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.

For additional information on BriaCell, please visit: http://www.BriaCell.com .

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com .

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

For further information, please contact:

BriaCell Therapeutics Corp.: Farrah Dean Manager, Corporate Development Email: Farrah@BriaCell.com Phone: 1-888-485-6340

Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 223

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 246

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Albion KAY VCT PLC's Strong Half-Year Performance Review

Updated Category News Views 95

Overview of Albion KAY VCT PLC Albion KAY VCT PLC plays a critical role in the investment landscape. The Company has recently published its Half-yearly Financial Report, which has garnered significant interest from both shareholders and potential investors. This report provides an in-depth look at the Company’s operations and financial condition over the six months...

Continue Reading
BlackRock Inc. Acknowledges Significant Stake in Syensqo

Updated Category News Views 160

Participation Notification by BlackRock Inc. In a recent communication, BlackRock Inc. has informed Syensqo of their increase in voting rights ownership, surpassing the critical threshold of 3%. This change is attributed to recent acquisitions or disposals of voting securities, which is in line with European transparency regulations. Details of the Notification The...

Continue Reading
Black Kite Unveils Innovative Global AI Risk Assessment Nexus

Updated Category News Views 204

Black Kite Launches Groundbreaking AI Assessment Framework Black Kite's GA³™ framework addresses a significant void in current global assurance frameworks. It creates a comprehensive standard that adapts to the ever-changing AI threat landscape. Importance of AI Risk Management Frameworks As cyber threats evolve, organizations face challenges in third-party risk...

Continue Reading
Purdue University Leads All-Boilermaker Mission with Virgin Galactic

Updated Category News Views 255

Purdue University Embarks on a Landmark Space Mission Building upon its rich legacy in space exploration, Purdue University is poised to undertake a remarkable journey — an all-Boilermaker crew will participate in a Virgin Galactic suborbital spaceflight known as Purdue 1. Set to launch in the near future, this mission opens up new avenues for academic exploration in...

Continue Reading
LP Building Solutions Provides Update on Q3 2024 Earnings Call

Updated Category News Views 77

LP Building Solutions Reveals Q3 2024 Earnings Call Details LP Building Solutions (NYSE: LPX), a prominent player in the building materials sector, has officially announced the schedule for its earnings conference call, set for an upcoming Tuesday. This anticipated event will highlight the financial results for the third quarter of 2024. Important Conference Call...

Continue Reading